Cyclacel Pharmaceuticals (NASDAQ:CYCC) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a report released on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Roth Capital cut Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd.

Cyclacel Pharmaceuticals Stock Performance

Shares of Cyclacel Pharmaceuticals stock opened at $0.36 on Friday. The business has a 50 day moving average of $0.38 and a 200 day moving average of $0.90. Cyclacel Pharmaceuticals has a 52 week low of $0.31 and a 52 week high of $4.00.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.36. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million.

Hedge Funds Weigh In On Cyclacel Pharmaceuticals

A hedge fund recently bought a new stake in Cyclacel Pharmaceuticals stock. Armistice Capital LLC bought a new position in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned 9.18% of Cyclacel Pharmaceuticals at the end of the most recent reporting period. 23.58% of the stock is owned by institutional investors and hedge funds.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.